Evidence map›Paper›PMID 39261343›Full record

ArticleFamilial cancer2024

Germline p.R181H variant in TP53 in a family exemplifying the genotype-phenotype correlations in Li-Fraumeni syndrome.

Claire Freycon, Laura Palma, Crystal Budd, Frederic Coulombe, Leora Witkowski, Pierre Hainaut, William D Foulkes, Catherine Goudie

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Familial cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Claire FreyconDepartment of Pediatrics, Division of Hematology-Oncology, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada. claire.freycon@muhc.mcgill.ca.ORCID 0009-0006-1963-5171
Laura PalmaDivision of Medical Genetics, Department of Specialized Medicine, McGill University Health Centre, Montreal, QC, Canada.
Crystal BuddDepartment of Child Health and Human Development, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Frederic CoulombeCore Molecular Diagnostic Laboratory, McGill University Health Centre, Montreal, QC, Canada.
Leora WitkowskiDepartment of Child Health and Human Development, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
Pierre HainautInstitute for Advanced Biosciences, Université Grenoble Alpes, Inserm 1209, CNRS 5309, Grenoble, France.
William D FoulkesDivision of Medical Genetics, Department of Specialized Medicine, McGill University Health Centre, Montreal, QC, Canada.
Catherine GoudieDepartment of Pediatrics, Division of Hematology-Oncology, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC, Canada.

Funding

CIHR
6 · The paper itself

Abstract

Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with germline pathogenic/likely pathogenic variants in TP53. Genotype-phenotype correlations are progressively being characterized in LFS with certain TP53 variants associated with attenuated penetrance and phenotypes. We report on a family harboring a TP53 p.R181H variant presenting with a restricted cancer phenotype in adulthood. The proband was a female with breast cancer at the age of 71 years who had three first degree relatives also diagnosed with breast cancer after the age of 40 years (mother, two sisters). Of the nine individuals harboring the variant (6 genetically confirmed, 3 obligate heterozygous), six have not developed malignancies at this time (age range: 36-42). No childhood-onset cancers were reported in this family. A concomitant literature review identified 51 additional individuals harboring the p.R181H variant in TP53, presenting a tumor phenotype dominated by breast cancer. Rare occurrences of other adult-onset cancers (prostate, colorectal and thyroid) and only few childhood onset cancer were documented. These observations are consistent with functional analysis showing that p.R181H retains partial p53 function and suggesting possible reduced cancer penetrance, particularly in the pediatric setting.

Indexed as

Germ-Line MutationLi-Fraumeni SyndromePedigreeTumor Suppressor Protein p53AdultAgedBreast NeoplasmsFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansMaleMiddle AgedPenetrancePhenotypeTP53 protein, humanTumor Suppressor Protein p53Genotype-phenotype correlationsLi-Fraumeni syndromep.R181H variantTP53 gene

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.